Tango Therapeutics, Inc. $TNGX Holdings Lowered by Janus Henderson Group PLC

Janus Henderson Group PLC lowered its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) by 9.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,394,972 shares of the company’s stock after selling 249,265 shares during the quarter. Janus Henderson Group PLC’s holdings in Tango Therapeutics were worth $50,067,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Tudor Investment Corp ET AL purchased a new stake in Tango Therapeutics during the third quarter valued at about $450,000. Mass General Brigham Inc purchased a new position in shares of Tango Therapeutics in the fourth quarter worth approximately $3,138,000. Candriam S.C.A. increased its position in shares of Tango Therapeutics by 79.1% in the first quarter. Candriam S.C.A. now owns 1,269,246 shares of the company’s stock worth $26,553,000 after acquiring an additional 560,434 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Tango Therapeutics by 33.6% during the fourth quarter. Vanguard Group Inc. now owns 6,750,977 shares of the company’s stock valued at $59,814,000 after acquiring an additional 1,698,974 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $1,906,000. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Price Performance

Shares of NASDAQ TNGX opened at $27.18 on Friday. Tango Therapeutics, Inc. has a one year low of $5.77 and a one year high of $34.39. The business’s 50-day moving average price is $27.68 and its two-hundred day moving average price is $21.18. The company has a market capitalization of $3.93 billion, a P/E ratio of -32.75 and a beta of 1.12.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.32). On average, equities analysts anticipate that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. B. Riley Financial reaffirmed a “buy” rating on shares of Tango Therapeutics in a research note on Monday, June 8th. Canaccord Genuity Group boosted their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Weiss Ratings lowered Tango Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. Piper Sandler cut Tango Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $16.00 to $24.00 in a research report on Thursday, May 14th. Finally, Wolfe Research set a $35.00 price target on Tango Therapeutics and gave the company an “outperform” rating in a report on Monday, June 8th. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $42.15.

Insider Activity at Tango Therapeutics

In related news, insider Adam Crystal sold 27,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the transaction, the insider owned 115,743 shares in the company, valued at approximately $3,424,835.37. This represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 6.50% of the company’s stock.

Tango Therapeutics Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.